North America Dominates Anti-Inflammatory Drugs Market with 45% Share, Driven by Rising Healthcare Investments | DataM Intelligence

Leander, Texas - The Global Anti-inflammatory Drugs Market reached US$102.72 billion in 2023 and is projected to grow to US$ 198.92 billion by 2031, registering a strong CAGR of 8.7% during 2024-2031.

This growth is driven by the rising prevalence of chronic inflammatory diseases, the expanding geriatric population, and the increased adoption of biologics and targeted therapies. Continuous R&D investments, along with the introduction of advanced anti-inflammatory formulations, are further boosting market expansion.

United States: Key Industry Developments

✅ October 2025: GlaxoSmithKline is expected to launch a novel biologic therapy targeting a specific inflammatory pathway for severe asthma, marking a significant advancement in personalised anti-inflammatory treatments.

✅ August 2025: Johnson & Johnson's subsidiary Janssen Pharmaceutical Companies launched a biosimilar of Stelara (ustekinumab), a targeted biologic for inflammatory diseases, expanding access to advanced anti-inflammatory therapies.

✅ April 2025: The FDA approved several next-generation NSAIDs with improved gastrointestinal safety profiles, reflecting an innovation focus on minimizing side effects in anti-inflammatory drug treatment.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/anti-inflammatory-drugs-market?ram

Japan: Key Industry Developments

✅ October 2025: Japanese manufacturers received increased subsidies from the government to invest in R&D for novel anti-inflammatory drugs and biologics targeting chronic inflammatory conditions, encouraging innovation in line with healthcare policy goals.

✅ September 2025: New clinical trials launched focusing on targeted small molecule inhibitors for specific inflammatory pathways, aiming for treatments with fewer off-target effects and better efficacy for diseases like rheumatoid arthritis.

✅ July 2025: Japan saw an increase in launches of biosimilar anti-inflammatory drugs, facilitating broader patient access to advanced biologic therapies and reducing treatment costs in the healthcare system.

Key Mergers and Acquisitions (2025):

✅ Johnson & Johnson - completed a $14.6 billion acquisition of Intra-Cellular Therapies, enhancing its portfolio with innovative central nervous system disorder therapeutics that overlap with anti-inflammatory indications.

✅ Merck & Co. - agreed to acquire Verona Pharma for $10 billion, adding respiratory-focused anti-inflammatory drugs such as ensifentrine (a PDE3/PDE4 inhibitor) to its cardio-pulmonary pipeline.

✅ Sanofi - completed a $9.5 billion acquisition of Blueprint Medicines, boosting its rare disease and specialty therapeutic pipeline, including drugs with anti-inflammatory applications.

✅ Endo Pharmaceuticals and Mallinckrodt - pending $6.7 billion merger aimed at strengthening their specialty pharma portfolios with a focus on inflammatory and pain management drugs.

✅ Eli Lilly and Company - acquired Scorpion Therapeutics' PI3Kα inhibitor program in a deal worth up to $2.5 billion, focusing on small molecule inhibitors with potential anti-inflammatory effects in cancer and advanced solid tumors.

Market Segmentation Analysis:

-By Drug Class: Anti-Inflammatory Biologics Lead Market Share at 32.56% in 2024
Anti-inflammatory biologics dominate with a 32.56% market share in 2024, driven by innovations in targeted immunomodulation and AI-enhanced drug discovery, with a CAGR of 8.43% projected through 2030. Nonsteroidal Anti-inflammatory Drugs (NSAIDs), corticosteroids, immune-selective derivatives (ImSAIDs), and others form the remainder of the market, with biologics leading due to their high specificity and efficacy.

-By Application: Arthritis Commands Largest Share at 48%
Arthritis leads the application segment with approximately 48%, followed by Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), asthma, tendonitis, and others. The growing prevalence of arthritis and inflammatory diseases fuels this trend.

-By Route of Administration: Oral Dominates with 45.57% Market Share
Oral administration holds the largest market share at 45.57% in 2024, favored for patient convenience and improved compliance with once-daily formulations. Injection is significant for biologics in acute care, while topical and inhalation routes are expanding due to advanced delivery technologies.

-By Distribution Channel: Hospital and Retail Pharmacies Lead
Hospital pharmacies remain crucial due to demand for specialized drugs, especially biologics. Retail pharmacies capture substantial share owing to OTC NSAIDs availability, complemented by growing online pharmacy channels adapting to digital healthcare trends.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=anti-inflammatory-drugs-market?ram (Purchase 2 or more Reports and get 50% Discount)

Emerging Players Reshaping the Anti-Inflammatory Drugs Market:

-UCB S.A.
Known for advancing novel interleukin inhibitors like Bimekizumab, UCB is gaining traction with promising clinical trials targeting psoriasis and other inflammatory diseases, signaling strong growth potential.

-Regeneron Pharmaceuticals, Inc.
Active in developing innovative monoclonal antibodies and biologics, Regeneron focuses on precision therapies for chronic inflammatory conditions, leveraging cutting-edge biotechnology to expand its therapeutic portfolio.

-Samsung Bioepis
A biosimilars specialist, Samsung Bioepis is expanding access to affordable anti-inflammatory biologics, notably TNF inhibitors, driving growth in emerging markets with a strong pipeline of biosimilar drugs.

-Aurobindo Pharma Limited
Focused on broad-spectrum anti-inflammatory generics and biosimilars, Aurobindo leverages cost-effective production and strategic global expansion to capture growing demand in both developed and emerging markets.

Growth Drivers:

-The rising prevalence of inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ulcerative colitis is a primary growth driver.

-The increasing aging population globally more prone to chronic inflammatory and autoimmune diseases fuels demand.

-Rising uptake of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) for respiratory diseases like asthma and COPD supports market expansion.

-Development and launch of novel anti-inflammatory biologics and biosimilars that are more targeted and effective with fewer side effects.

-Growing awareness, early diagnosis, and government backing promote treatment adoption and R&D investment.

-Expanding healthcare infrastructure and rising healthcare expenditure in emerging markets like Asia Pacific, Latin America, and Africa create new growth opportunities.

Regional Insights:

-North America (Largest Share): North America holds the largest market share, around 37-47%, driven by a high prevalence of chronic inflammatory diseases like arthritis and autoimmune disorders, a large aging population, and a well-established, advanced healthcare infrastructure. Strong adoption of advanced biologic therapies and biosimilars, supported by substantial pharmaceutical R&D investments and favorable regulatory frameworks, underpin this market dominance.

-Asia-Pacific (Fastest Growing): Asia-Pacific is the fastest-growing region with a CAGR around 8.5-11% projected through the late 2020s. This growth is fueled by rising healthcare expenditure, rapid urbanization, expanding patient populations with inflammatory disorders, growing awareness, improved diagnostic and treatment access, government initiatives, and expanding pharmaceutical manufacturing and clinical trials primarily in China, India, Japan, and Southeast Asia.

-Europe (Second Largest Share): Europe holds the second-largest market share, supported by robust research, high healthcare investment, biosimilar introductions reducing drug prices, and strong healthcare reimbursement policies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/anti-inflammatory-drugs-market?ram

Key Players:

Key players are Elicityl SA, Medolac Laboratories, Inbiose NV, Glycosyn, ZuChem, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, DuPont Nutrition & Health, and Nestlé Health Science.

Key Highlights (Top 5 Key Players) for Anti-Inflammatory Drugs Market:

-AbbVie Inc. reported USD 17.7 billion in revenue in 2024, driven primarily by its immunology drugs Skyrizi and Rinvoq, which successfully offset the revenue decline from Humira due to biosimilar competition.

-Johnson & Johnson Services, Inc. is one of the major players in the anti-inflammatory drugs market, contributing significantly to the market revenue alongside AbbVie, Pfizer, and Novartis.

-Pfizer Inc. is among the top revenue generators in the anti-inflammatory biologics market, part of the leading companies holding about 50-60% of the market share together with Merck and Novartis.

-F. Hoffmann-La Roche Ltd, known simply as Roche, is also a key player in this market with a strong immunology portfolio and biologics presence contributing to substantial sales.

-AstraZeneca holds a prominent position in the anti-inflammatory therapeutics market with a significant share supported by targeted therapies and biologics.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.